Highlighting Research Progress in Tau-Targeting Therapy for Alzheimer Disease: Diana Gallagher, MD

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]